STOCKHOLM, May 2, 2018 /PRNewswire/ -- Moberg Pharma
AB (OMX: MOB) announced that the United States Patent and
Trademark Office (USPTO) has issued Patent No. US 9,956,211 which
protects BUPI, currently in development for pain due to oral
mucositis. This patent should provide protection through to
2032.
The U.S. patent covers a method for the treatment of pain due to
oral mucositis in cancer patients by locally administering a
sustained-release lozenge in which the local anesthetic bupivacaine
is the active ingredient. This patent should provide protection
through to 2032. Moberg Pharma has previously announced patent
grants in Europe and Canada.
"This issuance of this patent in the United States is part of our overall
strategy to establish a broad portfolio of patent claims to protect
our proprietary products and is an important milestone, as we now
have granted patents in all territories where we have applied for
patent protection." commented Peter
Wolpert, Moberg Pharma's CEO.
In 2016, Moberg Pharma announced positive Phase 2 results with
BUPI in treating pain associated with oral mucositis in patients
with head and neck cancer undergoing radiotherapy. Moberg Pharma
estimates that the product has a sales potential amounting to USD
100–200 million annually, assuming successful commercialization in
oral mucositis and at least one further indication.
About this information
This information is information that Moberg Pharma AB is obliged
to make public pursuant to the EU Market Abuse Regulation. The
information was submitted for publication, through the agency of
the contact person set out above, at 8.30
a.m. CET on May 2nd, 2018.
For additional information, please contact:
Peter Wolpert,
CEO
Telephone: +1-908-432-22-03 (US), +46-70-735-71-35
E-mail: peter.wolpert@mobergpharma.se
Anna Ljung
CFO
Telephone: +46-707-66-60-30
E-mail: anna.ljung@mobergpharma.se
This information was brought to you by Cision
http://news.cision.com
http://news.cision.com/moberg-pharma/r/u-s--patent-granted-for-bupi,c2505536
The following files are available for download:
http://mb.cision.com/Main/1662/2505536/829436.pdf
|
U.S. patent granted
for BUPI
|
View original
content:http://www.prnewswire.com/news-releases/us-patent-granted-for-bupi-300640883.html
SOURCE Moberg Pharma